INCB057643: Clinical Trials

2 terminated. 2 Phase 1, 2 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	2	Terminated 2
Phase 2	2	Terminated 2

Follow INCB057643: new trials by email Literature Review of INCB057643 trials Research Report on INCB057643

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206) Azacitidine, Pembrolizumab, Epacadostat - Solid Tumors, Advanced Malignancies	Phase 1 / Phase 2	Terminated	Incyte Corporation	70	2017-02-27	2025-10-21
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies INCB057643, Gemcitabine, Paclitaxel - Solid Tumors	Phase 1 / Phase 2	Terminated	Incyte Corporation	137	2016-05-18	2025-10-21

Conditions studied

Breast Neoplasms (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Colorectal Neoplasms (1)  ·  Glioblastoma (1)  ·  Leukemia (1)  ·  Lymphoma (1)  ·  Lymphoma, Large B-Cell, Diffuse (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Multiple Myeloma (1)  ·  Myelodysplastic Syndromes (1)  ·  Myeloproliferative Disorders (1)  ·  Neoplasm Metastasis (1)  ·  Ovarian Neoplasms (1)  ·  Pancreatic Neoplasms (1)  ·  Primary Myelofibrosis (1)

Sponsors

Incyte Corporation (2)

Countries

United States (2)  ·  Belgium (1)  ·  France (1)  ·  Spain (1)  ·  United Kingdom (1)

Top investigators

Fred Zheng, MD, PhD (1)  ·  Kevin O'Hayer, MD (1)

Results publications

PMID 31527168

NIH funding

2016 (1), 2017 (1)